• Julia M Adam, D Jonathan Bennett, Anton Bom, John K Clark, Helen Feilden, Edward J Hutchinson, Ronald Palin, Alan Prosser, David C Rees, Georgina M Rosair, Donald Stevenson, Gary J Tarver, and Ming-Qiang Zhang.
• Department of Medicinal Chemistry, Organon Laboratories Ltd., Newhouse ML1 5SH, Scotland, UK.
• J. Med. Chem. 2002 Apr 25;45(9):1806-16.

AbstractA series of mono- and per-6-substituted cyclodextrin derivatives were synthesized as synthetic receptors (or host molecules) of rocuronium bromide, the most widely used neuromuscular blocker in anaesthesia. By forming host-guest complexes with rocuronium, these cyclodextrin derivatives reverse the muscle relaxation induced by rocuronium in vitro and in vivo and therefore can be used as reversal agents of the neuromuscular blocker to assist rapid recovery of patients after surgery. Because this supramolecular mechanism of action does not involve direct interaction with the cholinergic system, the reversal by these compounds, e.g., compound 14 (Org 25969), is not accompanied by cardiovascular side effects usually attendant with acetylcholinesterase inhibitors such as neostigmine. The structure-activity relationships are consistent with this supramolecular mechanism of action and are discussed herein. These include the effects of binding cavity size and hydrophobic and electrostatic interaction on the reversal activities of these compounds.

27 keywords...

hide…